首页 > 市场调查报告书 > 医疗设备

医学影像诊断

市场调查报告书

商品编码

1606515

全球人工智慧医疗影像解决方案市场 - 2024-2031

Global AI-Enabled Medical Imaging Solutions Market - 2024-2031

出版日期: 2024年12月04日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

2023年，全球人工智慧医疗影像解决方案市场规模达到11.2亿美元，预计2031年将达到126.4亿美元，2024-2031年预测期间复合年增长率为35.6%。

人工智慧医学影像解决方案是指将人工智慧（AI）技术整合到医学影像领域，以增强捕捉、分析、解释和报告诊断影像的过程。这些解决方案利用先进的人工智慧演算法，包括机器学习(ML)、深度学习(DL)、自然语言处理(NLP) 和电脑视觉，来自动化和改进医学影像工作流程的各个方面，例如影像增强、分割、解释和决策支援。

由于技术进步、医疗保健需求的增加以及放射学领域对人工智慧的日益偏好，市场对人工智慧医疗成像解决方案的需求正在快速增长。例如，根据北美放射学会的数据，在当前的医疗保健市场中，放射科医生的人工智慧工具占据主导地位。在 FDA 批准的 500 多种人工智慧演算法中，有 75% 的目标是放射学实践，这一比例从 70% 增加。

市场动态：

驱动程式和限制

人口老化加剧

人口老化的加剧正在显着推动人工智慧医疗成像解决方案市场的成长，预计将在预测期内推动该市场的发展。随着全球人口老化，癌症、心血管疾病、神经退化性疾病和肌肉骨骼疾病等与年龄相关的疾病的盛行率上升。这些情况需要频繁监测、早期检测和准确诊断，而藉助人工智慧成像解决方案可以更有效地实现这些目标。

人工智慧演算法可以帮助放射科医生更准确、更快速地分析医学影像，减少人为错误并提供更快的诊断。鑑于老年患者通常有多种健康状况需要立即评估，人工智慧优先考虑、分析和解释复杂医学影像的能力对于改善患者治疗效果至关重要。

例如，根据世界卫生组织的数据，到 2030 年，全世界每 6 人就有 1 人年龄在 60 岁或以上。此时，60岁及以上人口比例将从2020年的10亿增加到14亿。到 2050 年，全球 60 岁及以上人口将增加一倍（21 亿）。 2020 年至 2050 年间，80 岁及以上的人口数量预计将增加两倍，达到 4.26 亿。

此外，根据 NCOA 研究，近 95% 的 60 岁及以上成年人至少患有一种慢性病，而近 80% 的人患有两种或两种以上。而且，根据世界卫生组织的数据，癌症的发生率在生命的后期急剧上升。事实上，到 2022 年，约 53% 的癌症患者年龄在 65 岁或以上。事实证明，人工智慧影像可以有效地早期检测乳腺癌、肺癌和前列腺癌等癌症，这些癌症在老年人中更为常见。

资料隐私和安全问题

资料隐私和安全问题是阻碍人工智慧医学影像解决方案市场成长的重大挑战。这些担忧主要是由于医疗资料的敏感性、人工智慧系统的复杂性以及针对医疗机构的网路攻击事件的增加而引起的。

MRI 扫描、CT 扫描和 X 光等医学影像资料包含高度敏感的个人健康资讯。这些资料通常储存在基于云端的系统中或透过网路传输以进行人工智慧分析，因此很容易受到未经授权的存取。如果敏感的患者资料遭到洩露，不仅会危及个人隐私，还会损害医疗保健提供者和人工智慧供应商的声誉，可能导致患者失去信任并减少人工智慧技术的采用。

例如，科罗拉多州的一家病理实验室正在通知超过180 万名患者，他们的敏感资讯遭到洩露，这是医学检测实验室向美国联邦监管机构报告的最大违规行为之一，这使得医疗保健行业特别容易受到骇客的攻击。

AI-enabled medical imaging solutions refer to the integration of artificial intelligence (AI) technologies into the field of medical imaging to enhance the process of capturing, analyzing, interpreting and reporting diagnostic images. These solutions utilize advanced AI algorithms, including machine learning (ML), deep learning (DL), natural language processing (NLP) and computer vision to automate and improve various aspects of medical imaging workflows, such as image enhancement, segmentation, interpretation and decision support.

The market demand for AI-enabled medical imaging solutions is growing rapidly due to technological advancements, increasing healthcare needs and a growing preference for Artificial Intelligence in radiology. For instance, according to the Radiological Society of North America, in the current healthcare market, AI tools for radiologists dominate. Seventy-five percent of the over 500 FDA-cleared AI algorithms target radiology practice, increasing from 70%.

Market Dynamics: Drivers & Restraints

Rising aging population

The rising aging population is significantly driving the growth of the AI-enabled medical imaging solutions market and is expected to drive the market over the forecast period. As the global population ages, the prevalence of age-related diseases like cancer, cardiovascular conditions, neurodegenerative diseases and musculoskeletal disorders rises. These conditions require frequent monitoring, early detection and accurate diagnosis, which can be achieved more efficiently with AI-enabled imaging solutions.

AI algorithms can assist radiologists in analyzing medical images more accurately and swiftly, reducing human error and providing quicker diagnosis. Given that elderly patients often have multiple health conditions that need to be evaluated at once, AI's ability to prioritize, analyze, and interpret complex medical images is crucial for improving patient outcomes.

For instance, according to the World Health Organization, by 2030, 1 in 6 people in the world will be aged 60 years or over. At this time, the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world's population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million.

Additionally, According to NCOA research, nearly 95% of adults 60 and older have at least one chronic condition, while nearly 80% have two or more. And, according to the WHO, the incidence of cancer rises dramatically at a later stage in life. In fact, in 2022 about 53% of people who had cancer were 65 or older. AI-powered imaging has proven to be effective in early detection of cancers like breast cancer, lung cancer and prostate cancer conditions that are more prevalent in older adults.

Data privacy and security concerns

Data privacy and security concerns are significant challenges that are hampering the growth of the AI-enabled medical imaging solutions market. These concerns primarily arise due to the sensitive nature of medical data, the complexity of AI systems and the increasing incidents of cyberattacks targeting healthcare organizations.

Medical imaging data, such as MRI scans, CT scans and X-rays, contains highly sensitive personal health information. This data is often stored in cloud-based systems or transmitted over networks for AI analysis, making it vulnerable to unauthorized access. If sensitive patient data is compromised, it not only jeopardizes individual privacy but also damages the reputation of healthcare providers and AI vendors, potentially leading to loss of patient trust and reduced adoption of AI technologies.

For instance, a Colorado-based pathology laboratory is notifying more than 1.8 million patients that their sensitive information was compromised one of the largest breaches reported by a medical testing lab to US federal regulators, making the healthcare industry especially vulnerable to hackers.

Segment Analysis

The global AI-enabled medical imaging solutions market is segmented based on imaging modality, deployment mode, application, end-user and region.

Application:

The oncology segment is expected to dominate the global AI-enabled medical imaging solutions market share

The oncology segment holds a major portion of the AI-enabled medical imaging solutions market share and is expected to continue to hold a significant portion of the market share over the forecast period. his dominance is primarily driven by the critical need for early cancer detection, improved diagnostic accuracy and the growing adoption of AI technologies in oncology diagnostics.

Cancer is one of the leading causes of death worldwide. According to the World Health Organization (WHO), nearly 10 million people die from cancer each year. As cancer rates increase globally, the demand for effective diagnostic tools, including AI-powered medical imaging solutions, rises.

Early detection is crucial in improving cancer survival rates. AI has shown its potential to enhance the accuracy and speed of detecting cancers at an early stage. AI-enabled imaging solutions can analyze medical images (such as CT scans, MRIs, and mammograms) for early signs of cancer, enabling more effective and timely treatment.

For instance, the Harvard University team tested the AI tool, CHIEF (Clinical Histopathology Imaging Evaluation Foundation) performance on more than 19,400 whole-slide images from 32 independent datasets collected from 24 hospitals and patient cohorts across the globe. CHIEF achieved nearly 94 percent accuracy in cancer detection and significantly outperformed current AI approaches across 15 datasets containing 11 cancer types.

North America is expected to hold a significant position in the global AI-enabled medical imaging solutions market

North America region is expected to hold the largest market share over the forecast period. North America, particularly the United States and Canada, has some of the most advanced healthcare systems globally. These systems have the infrastructure and resources needed to implement and scale AI-driven medical imaging solutions.

For instance, the U.S. healthcare market is one of the largest in the world, with healthcare spending grew 4.1 percent in 2022, reaching $4.5 trillion or $13,493 per person, according to the Centers for Medicare & Medicaid Services (CMS). This substantial investment supports the adoption of cutting-edge technologies like AI in medical imaging to improve diagnostic accuracy and efficiency.

North America especially in the United States, is a global leader in artificial intelligence innovation, with tech giants heavily involved in the development of AI technologies for healthcare applications, including medical imaging. For instance, in April 2023, Exo cleared its FDA-cleared cardiac and lung artificial intelligence (AI) applications are available on Exo Iris, Exo's high-performance handheld ultrasound device. With affordable, AI-powered medical imaging in a pocket-sized device, caregivers can get answers immediately to accelerate diagnosis and create new care pathways for heart failure patients at the point of care.

Asia Pacific is growing at the fastest pace in the AI-enabled medical imaging solutions market

The Asia Pacific region is experiencing the fastest growth in the AI-enabled medical imaging solutions market. The Asia Pacific region is home to 60% of the world's population, with over 4.3 billion people. This large and diverse population presents a significant demand for healthcare services, including advanced diagnostic solutions like AI-powered medical imaging. As the population grows, so does the prevalence of health conditions such as cancer, cardiovascular diseases and neurological disorders, driving the demand for AI-powered diagnostic tools to help healthcare providers manage these conditions more effectively.

For instance, China and India, with populations over 1.4 billion and 1.4 billion respectively, are seeing a rise in diseases like lung cancer and diabetes, which are major drivers for the adoption of AI medical imaging tools in early detection and diagnosis.

Asia-Pacific countries are seeing a significant rise in chronic diseases, such as cancer, cardiovascular diseases and diabetes, necessitating the adoption of advanced diagnostic tools like AI-driven imaging to detect these diseases in their early stages. For instance, India has seen a rising incidence of cancer, with the Indian Council of Medical Research (ICMR) estimating that cancer cases will increase by more than 25% by 2035, highlighting the demand for AI-enabled imaging solutions for early diagnosis.

Competitive Landscape

The major global players in the AI-enabled medical imaging solutions market include deepc GmbH, Qure.ai Technologies Private Limited, DeepTek.ai, Inc, Aidoc, Tempus AI, Inc., Rayscape, Infervision, AIKENIST, Rad AI, Brainomix Limited and among others.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global artificial organs and bionics market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Imaging Modality
3.2. Snippet by Deployment Mode
3.3. Snippet by Application
3.4. Snippet by End-User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising Aging Population
  - 4.1.1.2. Rapid Analysis and Decision Making
- 4.1.2. Restraints
  - 4.1.2.1. Data Privacy and Security Concerns
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs

6. By Imaging Modality

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
- 6.1.2. Market Attractiveness Index, By Imaging Modality
6.2. X-ray Imaging*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Magnetic Resonance Imaging (MRI)
6.4. Computed Tomography (CT)
6.5. Ultrasound Imaging
6.6. Mammography
6.7. Others

7. By Deployment Mode

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
- 7.1.2. Market Attractiveness Index, By Deployment Mode
7.2. Cloud-Based Solutions*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. On-Premise Solutions
7.4. Hybrid Models

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Oncology*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cardiology
8.4. Neurology
8.5. Respiratory Disorders
8.6. Orthopedics
8.7. Gastroenterology
8.8. Others

9. By End-User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Diagnostic Centers
9.4. Specialty Clinics
9.5. Academic and Research Institutes

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.7.1. U.S.
  - 10.2.7.2. Canada
  - 10.2.7.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.7.1. Germany
  - 10.3.7.2. U.K.
  - 10.3.7.3. France
  - 10.3.7.4. Spain
  - 10.3.7.5. Italy
  - 10.3.7.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.7.1. Brazil
  - 10.4.7.2. Argentina
  - 10.4.7.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.7.1. China
  - 10.5.7.2. India
  - 10.5.7.3. Japan
  - 10.5.7.4. South Korea
  - 10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. deepc GmbH*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Qure.ai Technologies Private Limited
12.3. DeepTek.ai, Inc
12.4. Aidoc
12.5. Tempus AI, Inc.
12.6. Rayscape
12.7. Infervision
12.8. AIKENIST
12.9. Rad AI
12.10. Brainomix Limited

LIST NOT EXHAUSTIVE